SavedAdd your journal

Journals / Retina-Vitreus / 2000 / Cilt: 8 - Sayı: 1

Low dose cyclosporin-A use in the treatment of ocular Behçet's disease

Behçet hastalığına bağlı göz tutulumunda düşük doz siklosporin-A kullanımı

M. Pınar ÇAKAR
Serap ORTAÇ
Metin ÜNAL
Esin FIRAT
Pages
69–73
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We saw that the use of low dose CsA is effective in controlling the acute inflammation and reducing the frequency of ocular attacks in Behçet's disease.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:We investigated the efficacy of low dose cyclosporin-A (CsA) in ocular Behçet's disease in 67 eyes of 38 patients.
📊
Key Findings & Data:Twenty (20) patients were given CsA alone and 18 were given in combination with low dose prednisone.
💡
Conclusion & Impact:We saw that the use of low dose CsA is effective in controlling the acute inflammation and reducing the frequency of ocular attacks in Behçet's disease.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Enflamasyon · Tekrarlama · Behçet sendromu

Abstract

We investigated the efficacy of low dose cyclosporin-A (CsA) in ocular Behçet's disease in 67 eyes of 38 patients. Twenty (20) patients were given CsA alone and 18 were given in combination with low dose prednisone. Initial dose of CsA was 5 mg/kg/day in all patients. This dosage was gradually reduced to a maintenance level of 3 mg/kg/day. Ocular inflamation substantially resolved within the first two weeks of treatment. No ocular attacks occurred in 39 eyes (%58.2) Visual acuity improved in 26 eyes(%38.8), didn't change in 20(%29.9) and deteriorated in 21(%31.3). Thus visual acuity remained stable or improved in %68.7 of eyes over the course of therapy. No difference was observed in the improvement or stabilization of the visual acuity between the patients treated with CsA alone an the patients treated with combined CsA and prednisone (P>0.05). We saw that the use of low dose CsA is effective in controlling the acute inflammation and reducing the frequency of ocular attacks in Behçet's disease.

Özet

Siklosporin-A (CsA) nın düşük dozda uzun süreli kullanımının Behçet hastalığına bağlı göz tutulumunun tedavisindeki etkinliğini araştırmak amacıyla 38 hastaya ait 67 göz değerlendirildi. Hastalarımızın 20'si sadece CsA kullanırken, 18'i ek olarak düşük doz prednizon da almaktaydı. CsA uygulamamızı 5 mg/kg/gün başlangıç dozunu takiben 3 mg/kg/gün idame dozuna geçmek şeklindeydi. Tedaviyi takip eden ilk 2 hafta içerisinde oküler inflamasyon bulgularında belirgin azalma oldu, 39 gözde (%58.2) tedavi süresince yeni bir atak gelişmedi. 26 gözde (%38.8) görme artışı olurken, 20'sinde (%29.9) görme aynı kaldı, 21 gözde ise (%31.3) görme azaldı. Böylece tedavi süresince görmenin korunma veya artma oranı %68.7 idi. Tek başına CsA kullanan grup ile KS ile kombine kullanan grup arasında görme artışı ve korunması yönünden bir fark saptanmadı (P>0.05). Düşük dozda CsA kullanımının Behçet hastalığına bağlı göz tutulumunda akut inflamatuar reaksiyonu belirgin olarak baskıladığını, nüks gelişimini azalttığını gözledik.

🔖

Cite This Article

ÇAKAR, M. P., ORTAÇ, S., ÜNAL, M., FIRAT, E. (2000). Low dose cyclosporin-A use in the treatment of ocular Behçet's disease. Retina-Vitreus, Cilt: 8 - Sayı: 1, 69–73. https://ajindex.com/articles/305429

References (15)

  1. Nusenblatt RB, Palestine AG. Behçet's disease and other retinal vasculitidis In: Nusenblatt RB, Palestine AG. editors. Uveitis Fundamentals and Clinical Practice. Chicago, III. Year Book Medical Publishers
  2. 241 2. Atmaca LS, Gündüz K. Behçet hastalığı. Ret-vit: 1994
  3. 55 3. Nusenblatt RB, Palestine AG, Chan CC, Mochizuki M, Yancey K. Effectiveness of eyclosporin therapy for Behçet's disease. Arthritis and Rheumatism 1985
  4. 28(6): 671-679 4. Chavis PS, Antonios SR, Tabbara KF. Cyclosporine effects on optic nerve and retinal vasculitis in Behçet's disease. Documenta Ophhalmol 1992
  5. 42 5. Whitcup SM, Salvo EC, Nussenblatt RB. Combined eyclosporine and corticosteroid therapy for sight-threatening uveitis in Behçet's disease Am J Ophthalmol 1994
  6. 45 6. Nusenblatt RB, Palestine AG, Rook AN et al. Treatment of intraocular inflammatory disease with cyclos-porin A. The Lancet 1983
  7. 238 7. Müftüoğlu A, Pazarlı H, Yurdakul S et al Short term cyclosporin A treatment of Behçet's disease. Br J Ophthalmol 1987
  8. 390 8. Faulds D, Gaa K, Benfield P. Cyclosporin a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunregulatory disorders. Drugs 1993
  9. 45(6):953-1040 9. Özyazgan Y, Yurdakul S, Yazıcı H et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet's syndrome: a single masked trial. Br. J Ophthalmol 1992
  10. 243 10. BenEzra D, Maftzir G, Kalichman I, Barak V. Serum levels of interleukin-2 receptor in ocular Behçet's disease Am J Ophthalmol 1993
  11. 30 11. Binder Al, Graham ME et al. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987
  12. 283 12. Dick AD, Azim M, Forrester JV. Immunsupressive therapy for chronic uveitis: optimising therapy with steroids and cyclosporin A. Br J Ophthalmol 1997
  13. 1112 13. Atmaca LS, Batıoğlu F.The efficacy of cyclosporin-A in the treatment of Behçet's disease. Ophthalmic Surgery 1994
  14. 25(5):321-327 14. Pacor ML, Biasi D, Lunardi C et al. Cyclosporin in Behçet's disease results in 16 patients after 24 months of therapy. Clinical Rheumatol. 13 (2):224-7 15. Sajjadi H, Soheilian M, Ahmadich H et al. Low dose cyclosporin-A therapy in Behçet's disease. J Ocular Pharmacol 1994
  15. 10(3): 553-60 16. Smet MD, Rubin BI, Whitcup SM et al. Combined use of cyclosporine and ketoconazole in the treatmen of endogenous wveitis. Am J Ophthalmol 1992, 113: 687-690.